glp-1 drugs for prediabetes GLP-1-based therapies type 2 diabetes: from single, dual and triple agonists to endogenous production and L-cell differentiation | Diabetology & Metabolic Syndrome The expanding landscape of GLP-1

It is therefore likely that these drugs will succeed in counteracting the physiological adaptations normally caused by weight loss (increased appetite, in particular), but that these adaptations quickly take over after stopping the medication and promote the return to the initial overweight, before treatment

ZIP14, structurally similar to ZIP8, transports several divalent metals, including Mn, from the extracellular or organelle spaces into the cell cytosol (Tuschl et al., 2016

El Sayes, et al

Glycaemic status and cardiovascular disease in type 2 diabetes mellitus: Re-visiting glycated haemoglobin targets for cardiovascular disease prevention